Therapy in RCDII: Rationale for Combination Strategies?

Abstract

Refractory coeliac disease type II (RCDII) is characterized by a continuous gluten-independent duodenal immune activation with an extremely high risk of malignant transformation. It is therefore considered as an indolent lymphoma. RCDII is characterized by the presence of villous atrophy (Marsh III A-C) in combination with an aberrant intra- epithelial lymphocyte (IEL) population consisting of >20% sCD3-CD7+iCD3+ IELs. The sCD3-CD7+iCD3+ IELs are a heterogeneous lineage-negative cell population, consisting of cells that do or do not express CD127/IL7Rα. Experiments using IEL from non-RCDII patients have indicated that while the CD127- cells are IL-15 responsive, the CD127+ cells are not. Together with the observation that some patients express an aberrant (monoclonal) TCRγδ phenotype, this confirms the heterogeneity of the aberrant IEL population in RCDII and suggests that the aberrant cells are heterogeneous with respect to their response to common γ-chain cytokines. Although cladribine with or without autologous stem cell transplantation is effective in the treatment of signs and symptoms of RCDII and improves survival as compared to symptomatic topical steroid therapy, cladribine failures still bear a high risk of malignant transformation, and the rate of enteropathy-associated T-cell lymphoma (EATL) development in this subgroup is extremely high. It might be hypothesized that the heterogenous nature of aberrant IEL and the high risk of malignant transformation require a treatment strategy which is effective despite this heterogeneity. RCDII should be seen more in the light of a low-grade/no mass lymphoma or pre-EATL. We would suggest an upfront combination therapy approach integrating inhibition of downstream Jak-STAT signalling pathways with conventional therapy (2-CDA) to hopefully effectively treat signs and symptoms of RCDII and accomplish a more effective EATL prevention.

• Authors: Petula Nijeboer, Georgia Malamut, Gerd Bouma, Nadine Cerf-Bensussan, Frits Koning, Jeroen van Bergen, Christophe Cellier, Chris J J Mulder
• Journal: Digestive diseases (Basel, Switzerland) (Dig Dis) Vol. 33 Issue 2 Pg. 227-230 ( 2015) ISSN: 1421-9875 [Electronic] Switzerland
• PMID: 25925927 (Publication Type: Journal Article, Review)
• Copyright: © 2015 S. Karger AG, Basel.

Chemical References

• Cytokines

Topics

• Celiac Disease (therapy)
• Combined Modality Therapy
• Cytokines (metabolism)
• Genetic Heterogeneity
• Humans